LOS ANGELES, May 15 /PRNewswire-FirstCall/ -- MMR Information Systems, Inc. (OTC Bulletin Board: MMRF) (the "Company"), which was known as Favrille, Inc. until it acquired its subsidiary MyMedicalRecords, Inc. ("MMR") in January 2009, announced today that it had received a proposal to license certain of the Company's rights relating to a panel of anti-CD20 antibodies. Terms of the proposal were not announced.
In June 2007, prior to the MMR acquisition, then-named Favrille, Inc. announced that it had acquired from Diversa Corporation (now Verenium Corporation) a panel of anti-CD20 antibodies, along with the corresponding patents and an exclusive, royalty-free license to selected pending patents for commercialization of the panel.
Robert H. Lorsch, who became the Company's Chairman, President and Chief Executive Officer following the January 2009 acquisition of MMR, stated, "We are pleased to learn that there is renewed interest in the anti-CD20 antibodies assets of the Company. Clearly, the focus of our combined company following the MMR acquisition earlier this year will continue to be on the Company's primary products, which are the MyMedicalRecords Personal Health Record and MyEsafeDepositBox electronic safe deposit box storage solution. However, we are interested in monetizing other assets, and we are retaining an independent consulting firm to analyze these anti-CD20 antibody assets and to assist us in evaluating any proposal." Mr. Lorsch cautioned that, although discussions are ongoing, there can be no assurances that any licensing or other arrangement would be executed or, if executed, would provide any specified level of payments.
About MMR Information Systems, Inc.
MMR Information Systems, Inc. (formerly Favrille, Inc.), through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR"), provides secure and easy-to-use online Personal Health Records ("PHRs") an
|SOURCE MMR Information Systems, Inc.|
Copyright©2009 PR Newswire.
All rights reserved